S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush

bluebird bio (BLUE) Stock Forecast, Price & News

$3.31
-0.25 (-7.02%)
(As of 05/30/2023 ET)
Compare
Today's Range
$3.23
$3.68
50-Day Range
$2.79
$5.03
52-Week Range
$2.78
$8.58
Volume
3.05 million shs
Average Volume
4.32 million shs
Market Capitalization
$352.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
2.10 Rating Score
Upside/​Downside
101.4% Upside
$6.67 Price Target
Short Interest
Bearish
22.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.70mentions of bluebird bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.13) to ($1.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

376th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

51st out of 167 stocks


BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Vor Biopharma (VOR) Receives a Buy from Robert W. Baird
RBC Capital Sticks to Its Hold Rating for Bluebird Bio (BLUE)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
SVB Securities Keeps Their Hold Rating on Bluebird Bio (BLUE)
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates
What Wall Street expects from bluebird bio's earnings
bluebird bio (BLUE) Scheduled to Post Earnings on Tuesday
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings
5/09/2023
Today
5/30/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+101.4%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Net Income
$-266,580,000.00
Net Margins
-3,054.45%
Pretax Margin
-3,051.55%

Debt

Sales & Book Value

Annual Sales
$4.03 million
Book Value
$2.37 per share

Miscellaneous

Free Float
104,071,000
Market Cap
$352.22 million
Optionable
Optionable
Beta
0.89

Key Executives

  • Nick LeschlyNick Leschly
    Director
  • Andrew ObenshainAndrew Obenshain
    President, Chief Executive Officer & Director
  • Thomas J. Klima
    Chief Operating & Commercial Officer
  • Christopher Stanley Krawtschuk
    Chief Financial Officer
  • Richard Colvin
    Chief Medical Officer













BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2023?

10 Wall Street analysts have issued twelve-month price objectives for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they expect the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 101.4% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2023?

bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE shares have decreased by 52.2% and is now trading at $3.31.
View the best growth stocks for 2023 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.75. The biotechnology company had revenue of $2.40 million for the quarter, compared to analysts' expectations of $26.97 million. bluebird bio had a negative net margin of 3,054.45% and a negative trailing twelve-month return on equity of 52.40%. bluebird bio's revenue was up 26.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.66) EPS.

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (16.70%), BlackRock Inc. (8.41%), Pictet Asset Management SA (2.92%), Dimensional Fund Advisors LP (2.44%), Geode Capital Management LLC (1.97%) and Bank of America Corp DE (1.85%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $3.31.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $352.22 million and generates $4.03 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 518 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -